Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Microbix Biosystems Inc. (T:MBX)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Mostly sunny as of February 01, 2021
For the latest outlook, get the company report

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for MBX within the last 6 months
See all filings within the past 6 months

Company News

Feb 18, 2021 07:00 ET
Microbix Announces Issuance of Stock Options Using Shareholder-Approved Plan to Incentivize and Retain
Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its...
Read full article
Feb 16, 2021 07:00 ET
Microbix Announces Quality Products Distribution Agreement
Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces an agreement (Agreement) with Oneworld Accuracy Inc. (1WA) to distribute Microbix’s Quality Assessment Products (QAPs™) on a...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 28, 2021264,433-28,515
Feb 15, 2021292,948211,724
Jan 31, 202181,22430,156
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Microbix Biosystems Inc is a Canada-based life science company and manufacturer of viral and bacterial antigens and cell, culture-based biological products and technologies. The Company has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The Company's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.

See business summary



Search (past week) for $MBX.CA

  • No tweets found